Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2014 11:32 ET | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S establishes new Warrant Programme

Company Announcement no. 19/2014 To: NASDAQ OMX Copenhagen A/S ...
August 20, 2014 11:32 ET | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S etablerer warrantordning

Selskabsmeddelelse nr. 19/2014 Til: NASDAQ OMX Copenhagen A/S ...
August 20, 2014 11:17 ET | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals announces financial results for the first six months of 2014

Company Announcement no. 18/2014 To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 20 August, 2014 Veloxis Pharmaceuticals announces financial results for the first six...
August 15, 2014 04:17 ET | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 2. kvartal 2014 – resultater fra 1. januar til 30. juni 2014

Investor service meddelelse nr. 5/2014 Til: NASDAQ OMX København ...
August 15, 2014 04:17 ET | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for second Quarter 2014 – results from 1 January to 30 June, 2014

Investor service announcement no. 5/2014 To: NASDAQ OMX Copenhagen ...
July 28, 2014 02:30 ET | Source: Veloxis Pharmaceuticals A/S

Envarsus® får EMA markedføringstilladelse til behandling af såvel nyre- som levertransplantationspatienter

Selskabsmeddelelse nr. 17/2014 Til: NASDAQ OMX Copenhagen A/S ...
July 28, 2014 02:30 ET | Source: Veloxis Pharmaceuticals A/S

Envarsus® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients

Company Announcement no. 17/2014 To: NASDAQ OMX Copenhagen A/S ...
June 30, 2014 02:30 ET | Source: Veloxis Pharmaceuticals A/S

Envarsus® XR viser lavere forekomst af behandlingssvigt i afroamerikanere sammenlignet med to-gange-daglig tacrolimus (Prograf®)

Selskabsmeddelelse nr. 16/2014 Til: NASDAQ OMX Copenhagen A/S ...
June 30, 2014 02:30 ET | Source: Veloxis Pharmaceuticals A/S

Envarsus® XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus (Prograf®)

Company Announcement no. 16/2014 To: NASDAQ OMX Copenhagen A/S ...
June 23, 2014 10:49 ET | Source: Veloxis Pharmaceuticals A/S

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients

Company Announcement no. 15/2014 To: NASDAQ OMX Copenhagen A/S ...